For Research Use Only
MT-1 10mg Pen is supplied exclusively for in vitro laboratory research. Not for human or veterinary administration. Not an injection device for clinical or personal use. This material is not the authorised medicinal product Scenesse® (afamelanotide).
Regulatory Boundary Notice
Melanotan I (MT-1) shares its amino acid sequence with afamelanotide, the active substance in Scenesse® (authorised by the EMA for erythropoietic protoporphyria). The AbsoluteBioLab MT-1 10mg Pen is a research-grade preparation supplied exclusively for in vitro laboratory research. It is not the authorised medicinal product Scenesse® and is not supplied for clinical, therapeutic, or personal use.
MT-1 10mg Pen — Melanocortin Research Peptide Dispensing Format
The MT-1 10mg Pen is a pen-format research preparation of Melanotan I (MT-1, afamelanotide sequence), supplied as a pre-loaded cartridge for use with the AbsoluteBioLab Reusable Metal Peptide Pen v3 dispensing device. Each pen contains 10mg of MT-1 in a pen cartridge. The compound chemistry, analytical specification, and research context are documented on the canonical MT-1 10mg vial product page. Batch-specific analytical documentation is available through the AbsoluteBioLab CoA Portal.
Format Specification
| Attribute | Specification | Notes |
|---|---|---|
| Format | Pen cartridge — research dispensing format | Pre-loaded cartridge for use with Reusable Metal Peptide Pen v3 |
| Compound | Melanotan I (MT-1) — linear α-MSH analogue | Verify exact sequence, salt/counter-ion and CAS against batch-specific CoA |
| Nominal Mass | 10mg MT-1 | Verify against batch-specific CoA |
| Purity (RP-HPLC) | ≥99.0% | Compound-level CoA; verify against batch documentation |
| Identity (ESI-MS) | Confirmed | Compound-level CoA; verify against batch documentation |
| Compatible Device | Reusable Metal Peptide Pen v3 | Device page |
| Intended Use | Laboratory research dispensing | Research use only; not for human or veterinary administration |
Research Context
Melanotan I (MT-1) is a linear α-MSH analogue that acts at melanocortin receptors, with reported selectivity for MC1R in published in vitro studies. Research using MT-1 has examined MC1R binding, melanogenesis pathways, and photoprotection mechanisms in cell-based models. For the full research context, analytical specification, and scientific references, refer to the canonical MT-1 10mg vial product page. For a comparison of MT-1 and MT-2 receptor selectivity, refer to the Melanotan I vs Melanotan II Lab Comparison.
Researchers should note that MT-1 shares its sequence with afamelanotide, the active substance in Scenesse® (authorised by the EMA). The AbsoluteBioLab RUO material is not the authorised medicinal product and is supplied exclusively for in vitro laboratory research. Research findings from afamelanotide clinical studies are not directly applicable to the AbsoluteBioLab RUO material without independent experimental verification.
Batch Documentation
Compound-level CoA documentation is available via the AbsoluteBioLab CoA Portal. A compound-level CoA documents the peptide chemistry and does not constitute a finished-format batch record or device QC certificate.
Frequently Asked Questions
Is MT-1 the same as afamelanotide (Scenesse®)?
MT-1 (Melanotan I) shares its amino acid sequence with afamelanotide, the active substance in Scenesse® (authorised by the EMA for erythropoietic protoporphyria). The AbsoluteBioLab MT-1 10mg Pen is a research-grade preparation supplied exclusively for in vitro laboratory research. It is not the authorised medicinal product Scenesse® and is not supplied for clinical, therapeutic, or personal use.
What is the difference between MT-1 and MT-2?
MT-1 (Melanotan I) is a linear α-MSH analogue. MT-2 (Melanotan II) is a cyclic analogue with different receptor selectivity and pharmacological properties. Refer to the Melanotan I vs Melanotan II Lab Comparison for further information.
Reviews
There are no reviews yet.